- Home
- CADL vs ESPR Comparison
CADL vs ESPR Comparison
Compare CADL & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- ESPR
- Stock Information
- Founded
- CADL 1999
- ESPR 2008
- Country
- CADL United States
- ESPR United States
- Employees
- CADL N/A
- ESPR N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- CADL Health Care
- ESPR Health Care
- Exchange
- CADL Nasdaq
- ESPR Nasdaq
- Market Cap
- CADL 306.4M
- ESPR 305.0M
- IPO Year
- CADL 2021
- ESPR 2013
- Fundamental
- Price
- CADL $8.75
- ESPR $1.50
- Analyst Decision
- CADL Strong Buy
- ESPR Buy
- Analyst Count
- CADL 4
- ESPR 7
- Target Price
- CADL $21.00
- ESPR $6.36
- AVG Volume (30 Days)
- CADL 1.4M
- ESPR 3.9M
- Earning Date
- CADL 03-13-2025
- ESPR 03-04-2025
- Dividend Yield
- CADL N/A
- ESPR N/A
- EPS Growth
- CADL N/A
- ESPR N/A
- EPS
- CADL N/A
- ESPR N/A
- Revenue
- CADL N/A
- ESPR $332,314,000.00
- Revenue This Year
- CADL N/A
- ESPR $5.51
- Revenue Next Year
- CADL N/A
- ESPR $1.42
- P/E Ratio
- CADL N/A
- ESPR N/A
- Revenue Growth
- CADL N/A
- ESPR 185.66
- 52 Week Low
- CADL $1.34
- ESPR $1.47
- 52 Week High
- CADL $14.60
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- CADL 52.73
- ESPR 34.95
- Support Level
- CADL $7.65
- ESPR $1.47
- Resistance Level
- CADL $8.31
- ESPR $1.61
- Average True Range (ATR)
- CADL 0.92
- ESPR 0.13
- MACD
- CADL -0.10
- ESPR -0.01
- Stochastic Oscillator
- CADL 33.33
- ESPR 7.69
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.